Instil Bio Inc TIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $7.82
- Day Range
- $7.62–7.70
- 52-Week Range
- $5.67–33.83
- Bid/Ask
- $7.52 / $8.10
- Shares Outstanding
- 6.78M
- Market Cap
- $51.68M
- Volume/Avg
- 4,915 / 22,923
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.instilbio.com
Valuation
|
Metric
|
TIL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.47 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TIL
|
|---|---|
Quick Ratio | 15.79 |
Current Ratio | 39.87 |
Interest Coverage | −8.57 |
Quick Ratio
TIL
Profitability
|
Metric
|
TIL
|
|---|---|
Return on Assets (Normalized) | −18.29% |
Return on Equity (Normalized) | −31.90% |
Return on Invested Capital (Normalized) | −17.99% |
Return on Assets
TIL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|r@XY>$^ | LOCK|Y?m&< | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|YB&kVc | LOCK|%&N^ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|F#!R^L! | LOCK|#@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cNl#zw | LOCK|cRFC | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|x&!@X& | LOCK|QKn | $37B | |||
| Moderna Inc
MRNA
| LOCK|nfPzl? | LOCK|>$ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X&gSCs& | LOCK|l<>>? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|v&^%%q | LOCK|YZ | $23B | |||
| Incyte Corp
INCY
| LOCK|sC#dT#? | LOCK|<F | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|J?FSv# | LOCK|Fzb | $16B |
United States